A role for P-glycoprotein in clearance of alzheimer amyloid β-peptide from the brain

Current Alzheimer Research

Volumn 13, Issue 6, 2016, Pages 615-620

  Wang, Wei ^a   Bodles Brakhop, Angela M ^a,c   Barger, Steven W ^a,b,d  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c Inovio Pharmaceuticals   (United States)

^d GERIATRIC RESEARCH EDUCATION AND CLINICAL CENTER   (United States)

Author keywords

Alzheimer s disease; Amyloid peptide; Blood brain barrier; Blood cerebrospinal fluid barrier; MDR1; P glycoprotein; Transport

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; IODINE 125; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 1A; MULTIDRUG RESISTANCE PROTEIN 1B; PRESENILIN; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APP PROTEIN, HUMAN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 3; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BLOOD BRAIN BARRIER; BRAIN HISTOLOGY; BRAIN HOMOGENATE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE MUTATION; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TRANSPORT; ANIMAL; BRAIN; GENETICS; HUMAN; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE;

AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; AUTORADIOGRAPHY; BLOOD-BRAIN BARRIER; BRAIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MICE, TRANSGENIC; P-GLYCOPROTEINS; PEPTIDE FRAGMENTS;

EID: 84966326696     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205013666160314151012     Document Type: Article

References (34)

1. Glenner GG, Wong CW. Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun (3): 885-90 (1984).
2. De Strooper B, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, Annaert W, et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391(6665): 387-90 (1998).
3. Gregory GC, Halliday GM. What is the dominant Abeta species in human brain tissue? A review. Neurotox Res 7(1-2): 29-41 (2005).
4. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer’s disease. Am J Pathol 155(3): 853-62 (1999).
5. Campion D, Dumanchin C, Hannequin D, Dubois B, Belliard S, Puel M, et al. Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet 5(3): 664-70 (1999).
6. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, et al. Decreased clearance of CNS beta-amyloid in Alzheimer’s disease. Science 330(6012): 1774 (2010).
7. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57(2): 178-201 (2008).
8. Zhang W, Xiong H, Callaghan D, Liu H, Jones A, Pei K, et al. Blood-brain barrier transport of amyloid beta peptides in efflux pump knock-out animals evaluated by in vivo optical imaging. Fluids Barriers CNS 10(1):13 (2013).
9. Baranello RJ, Bharani KL, Padmaraju V, Chopra N, Lahiri DK, Greig NH, et al. Amyloid-beta protein clearance and degradation (ABCD) pathways and their role in Alzheimer’s disease. Curr Alzheimer Res 12(1): 32-46 (2015).
10. Qosa H, Abuasal BS, Romero IA, Weksler B, Couraud PO, Keller JN, et al. Differences in amyloid-beta clearance across mouse and human blood-brain barrier models: kinetic analysis and mechanistic modeling. Neuropharmacology 79: 668-78 (2014).
11. Sagare A, Deane R, Bell RD, Johnson B, Hamm K, Pendu R, et al. Clearance of amyloid-beta by circulating lipoprotein receptors. Nat Med 13(9): 1029-31 (2007).
12. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, et al. Clearance of Alzheimer’s amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 106(12): 1489-99 (2000).
13. Vogelgesang S, Cascorbi I, Schroeder E, Pahnke J, Kroemer HK, Siegmund W, et al. Deposition of Alzheimer’s beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics 12(7): 535-41 (2002).
14. Deo AK, Borson S, Link JM, Domino K, Eary JF, Ke B, et al. Activity of P-Glycoprotein, a beta-Amyloid Transporter at the Blood-Brain Barrier, Is Compromised in Patients with Mild Alzheimer Disease. J Nucl Med 55(7):1106-11 (2014).
15. Hartz AM, Miller DS, Bauer B. Restoring blood-brain barrier Pglycoprotein reduces brain amyloid-beta in a mouse model of Alzheimer’s disease. Mol Pharmacol 77(5): 715-23 (2010).
16. Rao VV, Dahlheimer JL, Bardgett ME, Snyder AZ, Finch RA, Sartorelli AC, et al. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc Natl Acad Sci USA 96(7): 3900-5 (1999).
17. Shi LZ, Li GJ, Wang S, Zheng W. Use of Z310 cells as an bloodcerebrospinal fluid barrier in vitro model: tight junction proteins and transport properties. Toxicol In Vitro 22(1): 190-9 (2008).
18. Miller DS, Bauer B, Hartz AM. Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy. Pharmacol Rev 60(2):196-209 (2008).
19. Kuhnke D, Jedlitschky G, Grube M, Krohn M, Jucker M, Mosyagin I, et al. MDR1-P-Glycoprotein (ABCB1) Mediates Transport of Alzheimer’s amyloid-beta peptides--implications for the mechanisms of Abeta clearance at the blood-brain barrier. Brain Pathol 17(4): 347-53 (2007).
20. Lam FC, Liu R, Lu P, Shapiro AB, Renoir JM, Sharom FJ, et al. beta-Amyloid efflux mediated by p-glycoprotein. J Neurochem 6(4): 1121-8 (2001).
21. Cirrito JR, Deane R, Fagan AM, Spinner ML, Parsadanian M, Finn MB, et al. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest 115(11): 3285-90 (2005).
22. van Assema DM, Lubberink M, Bauer M, van der Flier WM, Schuit RC, Windhorst AD, et al. Blood-brain barrier Pglycoprotein function in Alzheimer’s disease. Brain 135(Pt 1): 181-9 (2012).
23. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 1(1): a006189 (2011).
24. Yousif S, Marie-Claire C, Roux F, Scherrmann JM, Decleves X. Expression of drug transporters at the blood-brain barrier using an optimized isolated rat brain microvessel strategy. Brain Res 134(1): 1-11 (2007).
25. Zhu HJ, Liu GQ. Glutamate up-regulates P-glycoprotein expression in rat brain microvessel endothelial cells by an NMDA receptormediated mechanism. Life Sci 75(11): 1313-22 (2004).
26. Stanbury JB. Deiodination of the iodinated amino acids. Ann N Y Acad Sci 86: 417-39 (1960).
27. de Lange EC. Potential role of ABC transporters as a detoxification system at the blood-CSF barrier. Adv Drug Deliv Rev 56(12): 1793-809 (2004).
28. Sutcliffe JG, Hedlund PB, Thomas EA, Bloom FE, Hilbush BS. Peripheral reduction of beta-amyloid is sufficient to reduce brain beta-amyloid: implications for Alzheimer’s disease. J Neurosci Res 89(6): 808-14 (2011).
29. Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer’s disease. J Neurosci 21(2): 372-81 (2001).
30. Park R, Kook SY, Park JC, Mook-Jung I. Abeta1-42 reduces Pglycoprotein in the blood-brain barrier through RAGE-NF-kappaB signaling. Cell Death Dis 5: e1299 (2014).
31. Zhou SF. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 38(7-8): 802-32 (2008).
32. Sreenivasan S, Ravichandran S, Vetrivel U, Krishnakumar S. Modulation of multidrug resistance 1 expression and function in retinoblastoma cells by curcumin. J Pharmacol Pharmacother 4(2):103-9 (2013).
33. Green AK, Barnes DM, Karasov WH. A new method to measure intestinal activity of P-glycoprotein in avian and mammalian species. J Comp Physiol B 175(1): 57-66 (2005).
34. Bauer B, Hartz AM, Fricker G, Miller DS. Modulation of pglycoprotein transport function at the blood-brain barrier. Exp Biol Med (Maywood) 230(2): 118-27 (2005).